Clinical Trials Logo

Heart Failure NYHA Class III clinical trials

View clinical trials related to Heart Failure NYHA Class III.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04862273 Active, not recruiting - Clinical trials for Heart Failure With Preserved Ejection Fraction

Native T1 CMR Imaging for Diagnosis of Cardiac Amyloidosis

CMR for CA
Start date: April 1, 2021
Phase:
Study type: Observational

The study aims to test the diagnostic accuracy of native T1 mapping for the diagnosis of cardiac amyloidosis prospectively. The hypothesis is that native T1 mapping with a cut-off value of 1341ms (3 tesla CMR) in older patients with symptomatic heart failure, increased LV wall thickness and elevated cardiac biomarkers is non-inferior to the reference method to diagnose cardiac amyloidosis (CA). As secondary measure, a web-based ATTR probability estimator for the diagnosis of CA will be evaluated.

NCT ID: NCT04089059 Active, not recruiting - Clinical trials for Heart Failure NYHA Class III

PROACTIVE-HF IDE Trial Heart Failure NYHA Class III

PROACTIVE-HF
Start date: January 10, 2020
Phase: N/A
Study type: Interventional

This is a prospective, open- label, single arm, multicenter clinical trial to evaluate the safety and effectiveness of the Cordella PA Sensor System in NYHA Class III Heart Failure Patients compared to a Performance Goal (PG).

NCT ID: NCT04012944 Active, not recruiting - Clinical trials for Heart Failure NYHA Class III

SIRONA 2 Trial Heart Failure NYHA Class III

Start date: June 26, 2019
Phase: N/A
Study type: Interventional

This is a prospective, multi-center, open-label, single-arm CE-Mark trial to assess device safety and efficacy of the Cordella PA Sensor System in up to 75 New York Heart Association (NYHA) Class III Heart Failure patients who will receive the Cordella PA Sensor Implant.

NCT ID: NCT03375710 Active, not recruiting - Clinical trials for Heart Failure NYHA Class III

SIRONA Trial Heart Failure NYHA Class III

Start date: December 1, 2017
Phase: N/A
Study type: Interventional

This is a prospective, multi-center, open-label, single-arm feasibility trial to assess device safety and efficacy of the Cordella™ Heart Failure System in 10 NYHA Class III heart failure patients who will receive the Cordella™ Sensor implant.

NCT ID: NCT02880358 Active, not recruiting - Cardiogenic Shock Clinical Trials

Epidemiology and Prognostic of the Acute Heart Failure

EPICAL2
Start date: January 2011
Phase: N/A
Study type: Observational

EPICAL 2 (Epidemiology and prognostic of the Acute Heart Failure) is an epidemiological, observational, prospective and multicenter study. This study includes at first an exhaustive recording of the cases on a geographic area at East of France, then the recorded patients are followed up in a cohort at least 3 years. This study follows the experiences of the EPICAL study led by our team. Main objective: To describe the characteristics of the patients affected by acute heart failure and to identify prognostic factors, in particular related to care. More exactly : - To describe the sociodemographic, clinical, biological and therapeutic characteristics of the patients presenting an acute heart failure during hospitalisation and living at East of France ; - To study the short and medium-term morbi-mortality of these patients, and identify the main factors determining the prognosis for survival ; - To evaluate the prognostic impact of the intra and extra-hospital care ; - To identify the evolution of the care's practices of the decompensated heart failure since the EPICAL study (15 years) and their influence on the prognosis of the disease. Secondary objective: to constitute a biological collection of serum, plasma and urine of patients' sample presenting an acute heart failure.